|
21 Jan 2021 |
First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
|
|
21 Jan 2021 |
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea
|
|
21 Jan 2021 |
VBI Vaccines Announces Progress of Coronavirus Vaccine Program
|
|
21 Jan 2021 |
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
|
|
21 Jan 2021 |
Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV
|
|
20 Jan 2021 |
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
|
|
13 Jan 2021 |
AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform
|
|
12 Jan 2021 |
U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older
|
|
12 Jan 2021 |
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19
|
|
11 Jan 2021 |
Codagenix and Serum Institute of India Initiate Dosing in Phase 1 Trial of COVI-VAC, a Single Dose, Intranasal, Live Attenuated Vaccine for COVID-19
|
|
10 Jan 2021 |
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
|
|
10 Jan 2021 |
Affinivax Announces $226 Million Series C Financing to Advance Its Pipeline of Novel MAPS™ Vaccines Targeting Infectious Diseases
|
|
08 Jan 2021 |
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
|
|
07 Jan 2021 |
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
|
|
06 Jan 2021 |
Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform
|
|
06 Jan 2021 |
Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections
|
|
06 Jan 2021 |
INOVIO’s VGX-3100 demonstrates positive Phase 2 efficacy in treatment of precancerous vulvar dysplasia caused by HPV-16/18
|
|
06 Jan 2021 |
European Commission Authorizes COVID-19 Vaccine Moderna in Europe
|
|
06 Jan 2021 |
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
|
|
06 Jan 2021 |
Akston Biosciences and LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine
|
|
06 Jan 2021 |
Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
|
|
05 Jan 2021 |
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
|
|
02 Jan 2021 |
EpiVax and EpiVax Therapeutics Advance COVID-19 Vaccine Program, EPV-CoV-19
|
|
02 Jan 2021 |
Moderna Announces Publication of Results from the Pivotal Phase 3 Trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine
|
|
30 Dec 2020 |
AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK
|
